Oak Associates’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.9M | Sell |
156,362
-633
| -0.4% | -$97K | 1.61% | 19 |
|
|
2025
Q4 | $21.6M | Buy |
156,995
+1,136
| +0.7% | +$149K | 1.3% | 24 |
|
|
2025
Q3 | $20M | Sell |
155,859
-2,021
| -1% | -$247K | 1.22% | 23 |
|
|
2025
Q2 | $19.1M | Buy |
157,880
+5,481
| +4% | +$618K | 1.25% | 24 |
|
|
2025
Q1 | $17M | Buy |
152,399
+365
| +0.2% | +$38.9K | 1.27% | 24 |
|
|
2024
Q4 | $14.8M | Hold |
152,034
| – | – | 1.02% | 25 |
|
|
2024
Q3 | $17.5M | Buy |
152,034
+527
| +0.3% | +$59.8K | 1.18% | 24 |
|
|
2024
Q2 | $16.1M | Sell |
151,507
-651
| -0.4% | -$65.3K | 1.07% | 24 |
|
|
2024
Q1 | $14.7M | Sell |
152,158
-675
| -0.4% | -$69.2K | 1.02% | 28 |
|
|
2023
Q4 | $15.4M | Buy |
152,833
+4,794
| +3% | +$463K | 1.17% | 25 |
|
|
2023
Q3 | $15.1M | Buy |
148,039
+2,305
| +2% | +$234K | 1.25% | 23 |
|
|
2023
Q2 | $14.7M | Sell |
145,734
-31,025
| -18% | -$3.1M | 1.18% | 24 |
|
|
2023
Q1 | $16.3M | Buy |
176,759
+1,017
| +0.6% | +$88.8K | 1.34% | 22 |
|
|
2022
Q4 | $15.9M | Sell |
175,742
-9,340
| -5% | -$787K | 1.34% | 23 |
|
|
2022
Q3 | $14.1M | Sell |
185,082
-22,092
| -11% | -$1.83M | 1.19% | 28 |
|
|
2022
Q2 | $17.5M | Sell |
207,174
-1,846
| -0.9% | -$162K | 1.37% | 25 |
|
|
2022
Q1 | $18.3M | Sell |
209,020
-4,454
| -2% | -$386K | 1.12% | 27 |
|
|
2021
Q4 | $18.7M | Sell |
213,474
-1,604
| -0.7% | -$133K | 0.99% | 30 |
|
|
2021
Q3 | $17.6M | Hold |
215,078
| – | – | 1% | 30 |
|
|
2021
Q2 | $19.6M | Sell |
215,078
-1,250
| -0.6% | -$111K | 1.11% | 27 |
|
|
2021
Q1 | $18.5M | Sell |
216,328
-23,099
| -10% | -$2.07M | 1.09% | 29 |
|
|
2020
Q4 | $22.6M | Hold |
239,427
| – | – | 1.37% | 21 |
|
|
2020
Q3 | $20.8M | Sell |
239,427
-3,725
| -2% | -$323K | 1.39% | 22 |
|
|
2020
Q2 | $21.2M | Sell |
243,152
-3,141
| -1% | -$271K | 1.43% | 23 |
|
|
2020
Q1 | $20.3M | Sell |
246,293
-2,541
| -1% | -$227K | 1.67% | 17 |
|
|
2019
Q4 | $23.6M | Sell |
248,834
-5,220
| -2% | -$468K | 1.39% | 21 |
|
|
2019
Q3 | $22.1M | Sell |
254,054
-1,524
| -0.6% | -$137K | 1.36% | 25 |
|
|
2019
Q2 | $23.3M | Buy |
255,578
+21,114
| +9% | +$1.79M | 1.45% | 21 |
|
|
2019
Q1 | $20.2M | Buy |
234,464
+43,172
| +23% | +$3.47M | 1.23% | 29 |
|
|
2018
Q4 | $14.7M | Sell |
191,292
-2,011
| -1% | -$157K | 1.04% | 33 |
|
|
2018
Q3 | $14.9M | Buy |
193,303
+19,413
| +11% | +$1.44M | 0.91% | 38 |
|
|
2018
Q2 | $11.8M | Buy |
173,890
+157,262
| +946% | +$10.9M | 0.79% | 47 |
|
|
2018
Q1 | $1.21M | Hold |
16,628
| – | – | 0.08% | 103 |
|
|
2017
Q4 | $1.25M | Buy |
+16,628
| New | +$1.25M | 0.09% | 106 |
|
|
2016
Q2 | – | Sell |
-12,722
| Closed | -$826K | – | 168 |
|
|
2016
Q1 | $826K | Sell |
12,722
-4,576
| -26% | -$311K | 0.1% | 110 |
|
|
2015
Q4 | $1.33M | Sell |
17,298
-7,366
| -30% | -$585K | 0.16% | 102 |
|
|
2015
Q3 | $2.03M | Sell |
24,664
-1,674
| -6% | -$149K | 0.27% | 81 |
|
|
2015
Q2 | $2.32M | Hold |
26,338
| – | – | 0.28% | 82 |
|
|
2015
Q1 | $2.33M | Hold |
26,338
| – | – | 0.28% | 81 |
|
|
2014
Q4 | $2.19M | Hold |
26,338
| – | – | 0.26% | 86 |
|
|
2014
Q3 | $2.22M | Hold |
26,338
| – | – | 0.27% | 77 |
|
|
2014
Q2 | $2.14M | Hold |
26,338
| – | – | 0.26% | 82 |
|
|
2014
Q1 | $2.01M | Hold |
26,338
| – | – | 0.25% | 82 |
|
|
2013
Q4 | $1.9M | Buy |
+26,338
| New | +$1.83M | 0.21% | 85 |
|
|
2013
Q2 | $1.76M | Buy |
+27,788
| New | +$1.81M | 0.21% | 82 |
|
Other funds holding NVS
Oak Associates's NVS Position: Q1 2026 in Review
Oak Associates reduced its Novartis (NVS) stake by 0.4% in Q1 2026, selling an estimated $97K and leaving 156,362 shares worth $23.9M. The position accounts for 1.61% of the portfolio, ranked #19.
Oak Associates first reported a position in NVS in Q2 2013 and has held it in 45 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Oak Associates held 156,362 shares of Novartis worth $23.9M as of Q1 2026.
- Oak Associates sold 633 Novartis shares in Q1 2026, an estimated $97K.
- Novartis made up 1.61% of Oak Associates's portfolio in Q1 2026, its #19 holding.
- Oak Associates first reported a position in Novartis in Q2 2013 and has held it in 45 quarters since.
- 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Oak Associates's 13F filing for Q1 2026, filed 14 May 2026.